THE PROSTATE CANCER FOUNDATION named 24 Young Investigator Award winners. Members of the Class of 2016 were selected from a pool of 128 applicants from 77 institutions across 15 countries. Successful proposals included the use of genomics to predict prognosis and personalize treatments, as well as immunological approaches. The projects predominantly concentrated on treatment-resistant prostate...
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
